Tvardi Therapeutics annual revenue
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Tvardi Therapeutics Revenue Growth & History (TVRD)
Tvardi Therapeutics reported $0 in revenue for fiscal 2025, a decrease of 100.00% from the previous fiscal year.
View full Tvardi Therapeutics company overviewTvardi Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | −$7.1M | −100.00% |
| 2024 | 2024-12-31 | $7.1M | −$13.8M | −65.96% |
| 2023 | 2023-12-31 | $21.0M | −$20.9M | −49.92% |
| 2022 | 2022-12-31 | $41.9M | $18.8M | +81.81% |
| 2021 | 2021-12-31 | $23.0M | −$112.1M | −82.95% |
| 2020 | 2020-12-31 | $135.1M | $115.2M | +579.28% |
| 2019 | 2019-12-31 | $19.9M | $6.4M | +47.64% |
| 2018 | 2018-12-31 | $13.5M | $12.6M | +1378.49% |
| 2017 | 2017-12-31 | $911,000 | $825,000 | +959.30% |
| 2016 | 2016-12-31 | $86,000 | −$3.7M | −97.74% |
| 2015 | 2015-12-31 | $3.8M | $626,000 | +19.70% |
| 2014 | 2014-12-31 | $3.2M | −$8.8M | −73.45% |
| 2013 | 2013-12-31 | $12.0M | $10.8M | +905.38% |
| 2012 | 2012-12-31 | $1.2M | — | — |
Tvardi Therapeutics quarterly revenue
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | −$2.6M | −100.00% |
| Q4 2025 | 2025-12-31 | $0 | −$1.5M | −100.00% |
| Q3 2025 | 2025-09-30 | $0 | −$2.6M | −100.00% |
| Q2 2025 | 2025-06-30 | $0 | −$991,000 | −100.00% |
| Q1 2025 | 2025-03-31 | $2.6M | $434,000 | +20.33% |
| Q4 2024 | 2024-12-31 | $1.5M | −$1.5M | −51.56% |
| Q3 2024 | 2024-09-30 | $2.6M | −$2.3M | −47.47% |
| Q2 2024 | 2024-06-30 | $991,000 | −$5.9M | −85.71% |
| Q1 2024 | 2024-03-31 | $2.1M | −$4.0M | −65.37% |
| Q4 2023 | 2023-12-31 | $3.0M | −$257,000 | −7.88% |
| Q3 2023 | 2023-09-30 | $4.9M | −$5.9M | −55.00% |
| Q2 2023 | 2023-06-30 | $6.9M | −$16.1M | −69.86% |
| Q1 2023 | 2023-03-31 | $6.2M | $1.4M | +28.71% |
| Q4 2022 | 2022-12-31 | $3.3M | $2.4M | +297.20% |
| Q3 2022 | 2022-09-30 | $10.8M | −$9.5M | −46.66% |
| Q2 2022 | 2022-06-30 | $23.0M | $23.0M | — |
| Q1 2022 | 2022-03-31 | $4.8M | $2.9M | +147.55% |
| Q4 2021 | 2021-12-31 | $821,000 | −$111.3M | −99.27% |
| Q3 2021 | 2021-09-30 | $20.3M | $11.0M | +118.78% |
| Q2 2021 | 2021-06-30 | $0 | −$5.6M | −100.00% |
| Q1 2021 | 2021-03-31 | $1.9M | −$6.2M | −76.09% |
| Q4 2020 | 2020-12-31 | $112.1M | $107.6M | +2384.79% |
| Q3 2020 | 2020-09-30 | $9.3M | $3.5M | +60.17% |
| Q2 2020 | 2020-06-30 | $5.6M | $426,000 | +8.18% |
| Q1 2020 | 2020-03-31 | $8.1M | $3.7M | +84.69% |
| Q4 2019 | 2019-12-31 | $4.5M | −$1.0M | −18.47% |
| Q3 2019 | 2019-09-30 | $5.8M | $723,000 | +14.28% |
| Q2 2019 | 2019-06-30 | $5.2M | $2.3M | +81.21% |
| Q1 2019 | 2019-03-31 | $4.4M | — | — |
| Q4 2018 | 2018-12-31 | $5.5M | $5.5M | — |
| Q3 2018 | 2018-09-30 | $5.1M | $5.1M | — |
| Q2 2018 | 2018-06-30 | $2.9M | $2.9M | — |
| Q4 2017 | 2017-12-31 | $0 | $0 | — |
| Q3 2017 | 2017-09-30 | $0 | $0 | — |
| Q2 2017 | 2017-06-30 | $0 | −$79,000 | −100.00% |
| Q1 2017 | 2017-03-31 | $911,000 | $904,000 | +12914.29% |
| Q4 2016 | 2016-12-31 | $0 | $0 | — |
| Q3 2016 | 2016-09-30 | $0 | −$2.4M | −100.00% |
| Q2 2016 | 2016-06-30 | $79,000 | −$795,000 | −90.96% |
| Q1 2016 | 2016-03-31 | $7,000 | −$482,000 | −98.57% |
| Q4 2015 | 2015-12-31 | $0 | −$914,000 | −100.00% |
| Q3 2015 | 2015-09-30 | $2.4M | $1.3M | +116.89% |
| Q2 2015 | 2015-06-30 | $874,000 | −$86,000 | −8.96% |
| Q1 2015 | 2015-03-31 | $489,000 | $311,000 | +174.72% |
| Q4 2014 | 2014-12-31 | $914,000 | −$59,000 | −6.06% |
| Q3 2014 | 2014-09-30 | $1.1M | $107,000 | +10.51% |
| Q2 2014 | 2014-06-30 | $960,000 | −$9.0M | −90.37% |
| Q1 2014 | 2014-03-31 | $178,000 | — | — |
| Q4 2013 | 2013-12-31 | $973,000 | — | — |
| Q3 2013 | 2013-09-30 | $1.0M | — | — |
| Q2 2013 | 2013-06-30 | $10.0M | — | — |
Tvardi Therapeutics revenue growth trends
Tvardi Therapeutics's latest reported quarter, Q2 2026, generated $0 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Tvardi Therapeutics source filings ↗